The researchers said that they found their experimental COVID-19 vaccine produced a dual immune response in people aged 18 to 55.

COVID-19 Oxford vaccine phase 1 & 2 trails successful: Trails were conducted on 1077 people

WION Fineprint: Oxford COVID-19 vaccine early trail shows positive results

A closely watched coronavirus vaccine being developed by scientists at Oxford University appears protective in a small study of six monkeys, promising findings that led to the start of human trials late last month, US&nbsp;and British researchers reported on Thursday.

The preliminary findings, which have not undergone rigorous review by other scientists, appeared on the preprint server Biorxiv on Thursday.

According to the report, some of the monkeys given a single shot of the vaccine developed antibodies against the virus within 14 days, and all developed protective antibodies within 28 days, before being exposed to high doses of the virus.

After exposure, the vaccine appeared to prevent damage to the lungs and kept the virus from making copies of itself there, but the virus was still actively replicating in the nose.

Stephen Evans, a professor of pharmacoepidemiology at the london school of hygiene and&nbsp;tropical medicine, said the monkey data were “very definitely” good news.

''It is one of the hurdles to be passed by the oxford vaccine and it has cleared it well,''&nbsp;he said in an emailed comment. 
although success in monkeys is seen as a key step, many vaccines that protect monkeys in the lab ultimately fail to protect humans.

Evans said one-key finding was particularly reassuring,&nbsp;that there was no evidence of immune-enhanced disease, in which instead of protecting against a virus, a vaccine actually makes the disease worse.

''This was a definite theoretical concern for a vaccine against Sars-Cov-2 and finding no evidence for it in this study is very encouraging,''&nbsp;he said.

A closely watched coronavirus vaccine being developed by scientists at Oxford University appears protective in a small study of six monkeys, promising findings that led to the start of human trials late last month, US and British researchers reported on Thursday.

A closely watched coronavirus vaccine being developed by scientists at Oxford University appears protective in a small study of six monkeys, promising findings that led to the start of human trials late last month, US and British researchers reported on Thursday. The preliminary findings, which have not undergone rigorous review by other scientists, appeared on the preprint server Biorxiv on Thursday. According to the report, some of the monkeys given a single shot of the vaccine developed antibodies against the virus within 14 days, and all developed protective antibodies within 28 days, before being exposed to high doses of the virus. After exposure, the vaccine appeared to prevent damage to the lungs and kept the virus from making copies of itself there, but the virus was still actively replicating in the nose. Stephen Evans, a professor of pharmacoepidemiology at the london school of hygiene and tropical medicine, said the monkey data were “very definitely” good news. ''It is one of the hurdles to be passed by the oxford vaccine and it has cleared it well,'' he said in an emailed comment. although success in monkeys is seen as a key step, many vaccines that protect monkeys in the lab ultimately fail to protect humans. Evans said one-key finding was particularly reassuring, that there was no evidence of immune-enhanced disease, in which instead of protecting against a virus, a vaccine actually makes the disease worse. ''This was a definite theoretical concern for a vaccine against Sars-Cov-2 and finding no evidence for it in this study is very encouraging,'' he said.

Oxford coronavirus vaccine found 'protective' in small monkey study

A leading candidate for a Covid-19 vaccine has shown promising results in animal trials and is expected to see mass production in India within months.

Also read:&nbsp;<a href="https://www.wionews.com/world/when-will-coronavirus-end-in-us-uk-france-india-study-predicts-dates-month-295324">When will COVID-19 end in US, UK, France, India? Study predicts dates &amp; month</a>

The Serum Institute of India, the world’s largest maker of vaccines by volume, said on Tuesday that it plans this year to produce up to 60 million doses of a potential vaccine developed by the University of Oxford, which is under clinical trial in Britain.

<a href="https://www.wionews.com/world/uk-reports-586-covid-19-deaths-in-last-24-hours-death-toll-crosses-21600-295396">Also read |&nbsp;UK reports 586 COVID-19 deaths in last 24 hours; death toll crosses 21,600</a>

While the vaccine candidate, called “ChAdOx1 nCoV-19”, is yet to be proven to work against Covid-19, Serum decided to start manufacturing it as it had shown success in animal trials and had progressed to tests on humans, Serum Chief Executive Adar Poonawalla said.

Six rhesus macaque monkeys were inoculated with the vaccine candidate at the National Institutes of Health’s Rocky Mountain Laboratory in Montana last month, according to The New York Times.

The subjects were exposed afterwards to large quantities of the novel coronavirus, but all six remained healthy after more than 28 days, the newspaper reported, citing researcher Vincent Munster, who conducted the test.

More than 3 million people have been reported to be infected globally and over 210,000 have died from Covid-19, the respiratory disease caused by the coronavirus.

“They are a bunch of very qualified, great scientists [at Oxford] … That’s why we said we will go with this and that’s why we are confident,” Poonawalla told Reuters in a phone interview.

“Being a private limited company, not accountable to public investors or bankers, I can take a little risk and sideline some of the other commercial products and projects that I had planned in my existing facility,” Poonawalla said.

As many as 100 potential Covid-19 candidate vaccines are now under development by biotech and research teams around the world, and at least five of these are in preliminary testing in people in what is known as phase one clinical trials.

Poonawalla said he hoped trials of the Oxford vaccine, due to finish in about September, would be successful. Oxford scientists said last week the main focus of initial tests was to ascertain not only whether the vaccine worked but that it induced good immune responses and no unacceptable side effects.

Serum, owned by the Indian billionaire Cyrus Poonawalla, plans to make the vaccine at its two manufacturing plants in the western city of Pune, aiming to produce up to 400 million doses next year if all goes well, Poonawalla said.

“A majority of the vaccine, at least initially, would have to go to our countrymen before it goes abroad,” he said, adding that Serum would leave it to the Indian government to decide which countries would get how much of the vaccine and when.

Serum envisages a price of 1,000 rupees (US$14.70) per vaccine, but governments would give it to people without charge, he said.

He said Prime Minister Narendra Modi’s office was “very closely” involved in the vaccine production and the company is hoping the government will help foot the cost of making it.

Over roughly the next five months, Serum will spend some 300 million to 400 million rupees (US$4.4 million to US$5.9 million) on making around 3-5 million doses per month, he said. “[The government] are very happy to share some risk and fund something with us, but we haven’t really pencilled anything down yet,” Poonawalla said.

The serum has also partnered with the US biotech firm Codagenix and Austria’s Themis on two other Covid-19 vaccine candidates and plans to announce the fourth alliance in a couple of weeks, he said.

Serum’s board last week also agreed to invest roughly 6 billion rupees (US$8.8 billion) on making a new manufacturing unit to solely produce coronavirus vaccines, Poonawalla said.

A leading candidate for a Covid-19 vaccine has shown promising results in animal trials and is expected to see mass production in India within months. Also read: When will COVID-19 end in US, UK, France, India?

A leading candidate for a Covid-19 vaccine has shown promising results in animal trials and is expected to see mass production in India within months. Also read: When will COVID-19 end in US, UK, France, India? Study predicts dates & month The Serum Institute of India, the world’s largest maker of vaccines by volume, said on Tuesday that it plans this year to produce up to 60 million doses of a potential vaccine developed by the University of Oxford, which is under clinical trial in Britain. Also read | UK reports 586 COVID-19 deaths in last 24 hours; death toll crosses 21,600 While the vaccine candidate, called “ChAdOx1 nCoV-19”, is yet to be proven to work against Covid-19, Serum decided to start manufacturing it as it had shown success in animal trials and had progressed to tests on humans, Serum Chief Executive Adar Poonawalla said. Six rhesus macaque monkeys were inoculated with the vaccine candidate at the National Institutes of Health’s Rocky Mountain Laboratory in Montana last month, according to The New York Times. The subjects were exposed afterwards to large quantities of the novel coronavirus, but all six remained healthy after more than 28 days, the newspaper reported, citing researcher Vincent Munster, who conducted the test. More than 3 million people have been reported to be infected globally and over 210,000 have died from Covid-19, the respiratory disease caused by the coronavirus. “They are a bunch of very qualified, great scientists [at Oxford] … That’s why we said we will go with this and that’s why we are confident,” Poonawalla told Reuters in a phone interview. “Being a private limited company, not accountable to public investors or bankers, I can take a little risk and sideline some of the other commercial products and projects that I had planned in my existing facility,” Poonawalla said. As many as 100 potential Covid-19 candidate vaccines are now under development by biotech and research teams around the world, and at least five of these are in preliminary testing in people in what is known as phase one clinical trials. Poonawalla said he hoped trials of the Oxford vaccine, due to finish in about September, would be successful. Oxford scientists said last week the main focus of initial tests was to ascertain not only whether the vaccine worked but that it induced good immune responses and no unacceptable side effects. Serum, owned by the Indian billionaire Cyrus Poonawalla, plans to make the vaccine at its two manufacturing plants in the western city of Pune, aiming to produce up to 400 million doses next year if all goes well, Poonawalla said. “A majority of the vaccine, at least initially, would have to go to our countrymen before it goes abroad,” he said, adding that Serum would leave it to the Indian government to decide which countries would get how much of the vaccine and when. Serum envisages a price of 1,000 rupees (US$14.70) per vaccine, but governments would give it to people without charge, he said. He said Prime Minister Narendra Modi’s office was “very closely” involved in the vaccine production and the company is hoping the government will help foot the cost of making it. Over roughly the next five months, Serum will spend some 300 million to 400 million rupees (US$4.4 million to US$5.9 million) on making around 3-5 million doses per month, he said. “[The government] are very happy to share some risk and fund something with us, but we haven’t really pencilled anything down yet,” Poonawalla said. The serum has also partnered with the US biotech firm Codagenix and Austria’s Themis on two other Covid-19 vaccine candidates and plans to announce the fourth alliance in a couple of weeks, he said. Serum’s board last week also agreed to invest roughly 6 billion rupees (US$8.8 billion) on making a new manufacturing unit to solely produce coronavirus vaccines, Poonawalla said.

Coronavirus: Oxford vaccine effective in monkeys, heading for mass production in India

oxford-vaccine

Oxford Vaccine, News on Oxford Vaccine, stories on Oxford Vaccine, articles on Oxford Vaccine, Oxford Vaccine stories at Wion, Oxford Vaccine news, Oxford Vaccine latest news